The company has been very proactive in the area of partnering and licensing. To date, the company has completed agreements with six key partners: Alkem Laboratories, Union Springs Pharmaceuticals, Innovacyn, OroScience, China Bao Tai and Bayer Animal Health. As well, discussions continue with a number of prospective partners for the licensing of Microcyn in multiple applications.

Alkem Laboratories:
In 2006, Alkem Laboratories, one of India’s top 10 pharmaceutical companies, licensed the rights to the Microcyn Technology in India for use in wound care. Alkem has an impressive track record of building major brands with doctors and consumers. Alkem has commercialized its Microcyn wound care product under the brand name Oxum, its launch being the premier marketing event for Alkem in 2006.

Union Springs Pharmaceuticals :
In June of 2007, Oculus entered into an exclusive licensing agreement with Union Springs Pharmaceuticals, under which Oculus licensed rights to its Microcyn^® Technology for use in an over-the-counter first responder “pen-like” applicator intended for use by police, fire, military, emergency medical personnel, healthcare providers, homeland security personnel and consumers.

MyClyns™ is a topical post-exposure protection device that provides for a versatile, convenient and readily accessible first response spray.

Most recently, Union Springs introduced a consumer over-the-counter version of the MyClyns product with a national television advertising campaign, while making the product nationally available on retail shelves including CVS, Duane Reade, Kroger and many other outlets.

Innovacyn:
In early 2009, Oculus entered into a revenue-sharing partnership with Innovacyn (previously VetCure, Inc) for North American rights to the Vetericyn animal healthcare products. Innovacyn has demonstrated a real understanding of the animal healthcare market, including equine and companion animals, and has been most successful in promoting to the horse and cattle audience via a national advertising campaign on RFD-TV for rural America, and most recently a very compelling promotional effort with Cesar Millan of Dog Whisperer fame to reach the companion animal owners. In late 2009, Oculus announced that it had entered into a partnership with Innovacyn for the non-exclusive rights to market Microcyn-based skin and wound care over-the-counter products in the United States and Canada.

OroScience:
In July 2009, Oculus granted exclusive rights to OroScience, Inc. to market Microcyn-based oral products in the U.S., Canada and European professional dental and oral care markets while providing Oculus a significant percentage of those revenues. OroScience is applying for its first two FDA 510(k) clearances for an oral Microcyn rinse and a Microcyn HydroGel for mucositis in early 2010.

China Bao Tai:
In April of 2007, Oculus entered into an exclusive distribution agreement with China Bao Tai Investment Company, Ltd., for the rights to its Microcyn^®-based wound care solution in China. The Microcyn Technology will be packaged under China Bao Tai’s private label brand names in China.

China Bao Tai will utilize various sub-distributors for hospitals, independent pharmacies and retail pharmacies.

China Bao Tai has completed two randomized controlled clinical trials of shelf-stable Microcyn^® Technology in China, a 162-patient burn wound study and a 35-patient chronic would treatment study. This trial data was submitted to the Chinese State Food and Drug Administration (SFDA) in December 2007 and marketing approval was granted by the agency in March of 2008. Preparations are now underway for commercialization of the Microcyn Technology in China.

Bayer Animal Health:
In June 2008, Oculus entered into agreements with Bayer Australia Limited and Bayer (Sichuan) Animal Health Co. Ltd., for development of the Microcyn Technology for use in the Australian and Chinese animal health markets respectively. Upon receipt of necessary regulatory approvals, Bayer retains right of first negotiation to enter into a distribution agreement for Oculus’ Vetericyn™ animal brand (formulated with the Microcyn Technology) in those countries.